Company intelligence / Profile preview

Nervonik

Los Angeles, California, USAnervonik.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Nervonik has completed its first-in-human clinical trial of a proprietary wirelessly powered peripheral nerve stimulation device for chronic pain. The study demonstrated preliminary safety and device performance in patients with chronic shoulder or knee pain. Results are being compiled and will be presented in early/mid 2025. The company aims to advance toward regulatory clearance and commercialization as an opioid-free alternative to traditional treatments.

Therapeutic areas: RheumatologyNeurology
Modalities: DeviceNeuromodulation implantPeripheral nerve stimulation system (PNS)
Industry: Implantable Medical Devices

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Nervonik.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nervonik.

Explore the full profile